These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 10205992)

  • 1. Treatment of moderate or severe arterial hypertension with losartan.
    Dimitrova A; Todorova M; Bianov K; Halachev N; Dineva S; Elenkova A
    Folia Med (Plovdiv); 1998; 40(3B Suppl 3):43-5. PubMed ID: 10205992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
    Lee SE; Kim YJ; Lee HY; Yang HM; Park CG; Kim JJ; Kim SK; Rhee MY; Oh BH;
    Clin Ther; 2012 Mar; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators.
    Kassler-Taub K; Littlejohn T; Elliott W; Ruddy T; Adler E
    Am J Hypertens; 1998 Apr; 11(4 Pt 1):445-53. PubMed ID: 9607383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihypertensive and renoprotective efficacy and safety of losartan. A long-term study in children with renal disorders.
    Ellis D; Moritz ML; Vats A; Janosky JE
    Am J Hypertens; 2004 Oct; 17(10):928-35. PubMed ID: 15485756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter, randomized, double-blind, placebo-controlled, 8-week trial of the efficacy and tolerability of once-daily losartan 100 mg/hydrochlorothiazide 25 mg and losartan 50 mg/hydrochlorothiazide 12.5 mg in the treatment of moderate-to-severe essential hypertension.
    Gradman AH; Brady WE; Gazdick LP; Lyle P; Zeldin RK
    Clin Ther; 2002 Jul; 24(7):1049-61. PubMed ID: 12182251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Collaborative Group.
    Toto R; Shultz P; Raij L; Mitchell H; Shaw W; Ramjit D; Toh J; Shahinfar S
    Hypertension; 1998 Feb; 31(2):684-91. PubMed ID: 9461241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension.
    Hedner T; Oparil S; Rasmussen K; Rapelli A; Gatlin M; Kobi P; Sullivan J; Oddou-Stock P
    Am J Hypertens; 1999 Apr; 12(4 Pt 1):414-7. PubMed ID: 10232502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the blood pressure-lowering effects and tolerability of Losartan- and Amlodipine-based regimens in patients with isolated systolic hypertension.
    Volpe M; Junren Z; Maxwell T; Rodriguez A; Gamboa R; Gomez-Fernandez P; Ortega-Gonzalez G; Matadamas N; Rodriguez F; Dass B; Kyle C; Clarysse L; Bryce A; Moreno-Heredia E; Germano G; Gilles L; Smith RD; Sanderson JE;
    Clin Ther; 2003 May; 25(5):1469-89. PubMed ID: 12867222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The safety of long-term administration of losartan in current clinical practice: a non-intervention NCT-CZ 14/04/LOZ study].
    Krupicka J; Ceypová K; Kristenová P; Hauser T
    Vnitr Lek; 2008 Nov; 54(11):1031-8. PubMed ID: 19069675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension.
    Mallion J; Siche J; Lacourcière Y
    J Hum Hypertens; 1999 Oct; 13(10):657-64. PubMed ID: 10516734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term anti-proteinuric effect of Losartan in renal transplant recipients treated for hypertension.
    Calviño J; Lens XM; Romero R; Sánchez-Guisande D
    Nephrol Dial Transplant; 2000 Jan; 15(1):82-6. PubMed ID: 10607772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study on the efficacy and safety of losartan in elderly patients with mild to moderate essential hypertension.
    Fernández-Vega F; Abellan J; Sanz de Castro S; Cucalón JM; Maceira B; Gómez de la Cámara A
    Int Urol Nephrol; 2001; 32(4):519-23. PubMed ID: 11989539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Angiotensin-II receptor inhibitors in hemodialysed uremia patients with arterial hypertension: candesartan cilexitil versus losartan].
    Cice G; Ferrara L; Tagliamonte E; Russo PE; Di Benedetto A; Iacono A
    Cardiologia; 1999 Dec; 44(12):1071-6. PubMed ID: 10687258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators.
    Oparil S; Guthrie R; Lewin AJ; Marbury T; Reilly K; Triscari J; Witcher JA
    Clin Ther; 1998; 20(3):398-409. PubMed ID: 9663357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan study investigators.
    Lacourcière Y; Asmar R
    Am J Hypertens; 1999 Dec; 12(12 Pt 1-2):1181-7. PubMed ID: 10619580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of the long-term treatment with losartan and captopril and of the abrupt cessation on circadian blood pressure profile].
    Gorbunov VM; Savina LV; Metelitsa VI; Deev AD
    Eksp Klin Farmakol; 2001; 64(2):45-50. PubMed ID: 11548448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Losartan and renal transplantation.
    Horn S; Holzer H; Horina J
    Lancet; 1998 Jan; 351(9096):111. PubMed ID: 9439500
    [No Abstract]   [Full Text] [Related]  

  • 18. A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring.
    Baguet JP; Nisse-Durgeat S; Mouret S; Asmar R; Mallion JM
    Int J Clin Pract; 2006 Apr; 60(4):391-8. PubMed ID: 16620350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise.
    Warner JG; Metzger DC; Kitzman DW; Wesley DJ; Little WC
    J Am Coll Cardiol; 1999 May; 33(6):1567-72. PubMed ID: 10334425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of long-term antihypertensive therapy with losartan on blood pressure and cognitive function in patients with essential hypertension and other cerebrovascular risk factors (AWARE observational study)].
    Schrader J; Lüders S; Diener HC; Haller H; Schmieder RE; Wahle K; Smolka W; Jung C; Bestehorn K
    Med Klin (Munich); 2008 Jul; 103(7):491-9. PubMed ID: 18604484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.